Ratings Novogene Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
15.77 ^CNY	-2.17%		+10.28%	-32.43%

Apr. 12	Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 27	Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.92 times its estimated earnings per share for the ongoing year.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

	1st Jan change	Capi.	ESG Refinitiv
NOVOGENE CO., LTD.	-32.43%	921M	-
SONIC HEALTHCARE LIMITED	-17.08%	8.39B	B+
RADNET, INC.	+52.46%	3.74B	C+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-37.54%	2.55B	B-
SYNLAB AG	-9.63%	2.48B	-
DR. LAL PATHLABS LIMITED	-13.43%	2.32B	B-
NEOGENOMICS, INC.	-6.12%	1.93B	C-
FLEURY S.A.	-18.57%	1.6B	A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-37.21%	1.28B	C+
METROPOLIS HEALTHCARE LIMITED	+5.14%	1.08B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality